Senores Pharmaceuticals Limited

Senores Pharmaceuticals Limited is a research-driven pharmaceutical company that develops and manufactures a range of specialty, complex, and generic pharmaceutical products, with a primary focus on regulated markets including the United States, Canada, and the United Kingdom, alongside a growing presence in emerging markets. Its portfolio spans multiple therapeutic areas and dosage forms. As of its IPO filing, the company had over 180 products registered across more than 40 countries, with a substantial number of additional filings pending regulatory approval. It operates FDA-approved manufacturing capacity and has been investing in expanding its sterile injectable manufacturing through its Havix facility. The promoter group consists of Swapnil Jatinbhai Shah and Ashokkumar Vijaysinh Barot. The company has shown strong revenue and profit growth in recent years as it has scaled its regulated-market product portfolio. The IPO combined a fresh issue used mainly to fund facility expansion and debt repayment with a smaller offer for sale, and the issue drew very heavy institutional and retail demand at listing.

Senores Pharmaceuticals raised about Rs 260.6 crore from anchor investors a day before the IPO opened, allotting shares at the upper price band of Rs 391. Domestic participants included ICICI Prudential Mutual Fund, Aditya Birla Sun Life Insurance, Mahindra Manulife, Bank of India Mutual Fund, SBI General Insurance, and Edelweiss Life Insurance, alongside international investors such as Goldman Sachs, Societe Generale, and Beacon Stone Capital.